Evading apoptosis by upregulation of BCL2 contributes to tumor initiation and maintenance (9, 10), thereby targeting BCL2 is currently becoming an attractive therapeutic approach for the treatment of various malignant disorders. Here, BCL2 is linked to neoplasm.